ArticleCell stem cell2020
Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed "Stem Cell Treatments" for COVID-19.
Article in Cell stem cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Safety Assessment of Extracellular Vesicle-Based Therapy in Regenerative Dentistry.International journal of molecular sciences · 2026Review
- Myths and Realities about the Private Sector Stem Cell Industry in Malaysia.Asian bioethics review · 2025Article
- The evolution and ongoing challenge of unproven cell-based interventions.Stem cells translational medicine · 2024Review
- Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims.Stem cell reports · 2023Article
- The Art of Stem Cell-Based Therapy.Advances in experimental medicine and biology · 2023Article
- The Early Detection of Fraudulent COVID-19 Products From Twitter Chatter: Data Set and Baseline Approach Using Anomaly Detection.JMIR infodemiology · 2023Article
- Clinical use of autologous cell-based therapies in an evolving regulatory landscape: A survey of patient experiences and perceptions.F1000Research · 2023Article
- International stem cell tourism: a critical literature review and evidence-based recommendations.International health · 2022Review
- Online seminars as an information source for direct-to-consumer stem cell therapy.Regenerative medicine · 2022Article
- Developing a Paradigm Model for Resilience of Rural Entrepreneurial Businesses in Dealing With the COVID-19 Crisis; Application of Grounded Theory in Western of Iran.Frontiers in public health · 2022Article
- Ethical issues and public communication in the development of cell-based treatments for COVID-19: Lessons from the pandemic.Stem cell reports · 2021Review
- Article
- Unproven stem cell interventions: A global public health problem requiring global deliberation.Stem cell reports · 2021Review
- Review
- Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System.Frontiers in immunology · 2021Article
- RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe-Why the European Union Should Invest More!Frontiers in medicine · 2021Article
- Deficiencies in the Designs and Interventions of COVID-19 Clinical Trials.Med (New York, N.Y.) · 2020Article
- Stem cell 'therapy' advertisements in China: Infodemic, regulations and recommendations.Cell proliferation · 2020Review
- The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.Stem cells translational medicine · 2020Review
- Combating COVID-19 With Mesenchymal Stem/Stromal Cell Therapy: Promise and Challenges.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.